Group A and Group C Meningococcal Polysaccharide Conjugate Vaccine

The meningococcal polysaccharideconjugate vaccine is prepared by using the culture solution of Neisseriameningitidis of group A and group C, extracting the obtained capsularpolysaccharide antigen, combining with tetanus toxoid, adding aluminumhydroxide adjuvant, and adsorbing. Mainly used for children over 2 years oldand adults, to prevent some infectious diseases caused by meningococcus, suchas cerebrospinal meningitis, coccal pneumonia, etc., to improve children'sresistance to these pathogenic microorganisms. After inoculation with thisvaccine, the body can produce a memory immune response. However, meningococcalpolysaccharide conjugate vaccine cannot prevent infections caused by othergerms, nor can it prevent meningitis, pneumonia and other diseases caused byother causes.

Meningococcal polysaccharideconjugate vaccine is a live attenuated vaccine. After the vaccine is injected,be careful not to eat spicy, irritating and cold food in your diet. You can eatmore vegetables and fruits rich in vitamins, drink more water, and avoidoverwork; It is also necessary to observe the mental state to avoid allergicreactions to the vaccine. In addition, the meningococcal polysaccharide conjugatevaccine belongs to the first category of vaccines, and the first category ofvaccines are provided free of charge by the state. Timely injection of vaccinescan prevent and control the spread of infectious diseases.

Types of vaccines

Currently available meningococcalpolysaccharide vaccines in China include: group A meningococcal polysaccharidevaccine, group A group C meningococcal polysaccharide vaccine, and groupACYW135 meningococcal polysaccharide vaccine. The scope of application of eachtype of vaccine is different.

Adverse reactions

Common adverse reactions: ①Within24 hours after inoculation, pain and tenderness may be felt at the injectionsite, and local redness, swelling and infiltration of the injection site areweak and moderate, and in most cases, it will disappear automatically within 2to 3 days. ②The vaccinated person may have atransient febrile reaction within 1 to 2 weeks after the vaccination. Most ofthe febrile reactions are mild febrile reactions, which usually resolvespontaneously after 1 to 2 days without treatment. If necessary, takeappropriate rest, drink plenty of water, and keep warm to prevent secondaryinfection; for moderate febrile reactions or fever If the time exceeds 48hours, physical or drug methods can be given for symptomatic treatment.

Rare adverse reactions: ①Forsevere febrile reactions, physical and drug methods should be given forsymptomatic treatment to prevent febrile convulsions. ②Forsevere redness and swelling or other complications at the injection site, applyhot compress with a clean towel several times a day for 10 to 15 minutes eachtime.

Very rare adverse reactions: ①Allergicrash: Individual vaccinators may develop rash within 72 hours aftervaccination, and should seek medical treatment in time for anti-allergictreatment. ②Anaphylactic shock: usually occurswithin 1 hour after the injection of the vaccine. It should be rescued in timeand treated with epinephrine injection. ③Allergicpurpura: Very few vaccinated patients may have allergic purpura cases. Whenallergic purpura reactions occur, they should seek medical treatment in time,and use corticosteroids to give anti-allergic standard treatment. Impropertreatment Or not in time may be complicated by purpuric nephritis. ④Occasionallyangioedema, allergic demyelinating neuritis. ⑤Ithas been reported in the literature that very few recipients may have allergicexfoliative dermatitis.

Taboo

(1)  Known allergy to any component ofthe vaccine.

(2) Those suffering from acutediseases, severe chronic diseases, acute exacerbations of chronic diseases andfever.

(3) For encephalopathy,uncontrolled epilepsy and other progressive neurological diseases.

Precautions

(1) Use with caution in thefollowing situations: family and personal history of convulsions, chronicdiseases, history of epilepsy, allergic constitution, lactating women.

(2) Vaccine bottles with cracks,unclear labels or invalid, and abnormal turbidity after reconstitution of thevaccine should not be used.

(3) Drugs such as epinephrineshould be prepared for emergency use in case of occasional severe allergicreaction. Those receiving the injection should observe the scene for at least30 minutes after the injection.

(4) There should be at least 1month interval between the vaccination of this product and the injection ofimmune globulin, so as not to affect the immune effect.

Conclusion

Because meningococcal meningitis iscontagious, vaccination with meningococcal polysaccharide conjugate vaccine isthe most effective way to prevent meningococcal meningitis. In addition, properphysical exercise, enhancing self-immunity, establishing good living habits orblocking transmission routes can play a role in preventing the occurrence ofdiseases.